- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04377737
Incidence of Covid-19 in School Children (COVIDECOLE)
Incidence of Covid-19 in School Children During the Pandemic Period in Nice
The Coronavirus disease 2019 (COVID-19) is causing a global pandemic with high morbidity and mortality among adults and mainly the elderly. Children seem to be little or not affected by this infection. It is estimated that children could be asymptomatic or pauci-symptomatic carriers and thus be vectors of the disease. This is why measures to close schools and confine populations have been decreed in a large number of countries, including France. However, there are only a few data on the prevalence of COVID19 disease in children. The deconfinement strategy depends on data on the prevalence of the disease, especially in children.
Investigators propose to evaluate the incidence of Covid-19 in preschool and elementary schools children in the city of Nice (South of France) during the pandemic period using a local prospective study of 914 children
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The Coronavirus disease 2019 (COVID-19) is causing a global pandemic with high morbidity and mortality among adults and mainly the elderly. Children seem to be little or not affected by this infection. It is estimated that children could be asymptomatic or pauci-symptomatic carriers and thus be vectors of the disease. However, the role of the children in the spread of COVID-19 injection remains unclear.
Measures to close schools and to confine populations have been decreed in a large number of countries, including France. This decision has been based on epidemiologic data of other viral infections having droplet transmission and on data of Middle East Respiratory Syndrome-related coronavirus (MERS-CoV) asymptomatic portage.
Furthermore, there are only a few data on the prevalence of COVID19 disease in children. The deconfinement strategy depends on data on the prevalence of the disease, especially in children.
Therefore, investigators propose to evaluate the incidence of Covid-19 in preschool and elementary schools children in the city of Nice (South of France) during the pandemic period using a local prospective study of 914 children.
This study will start on 11th May 2020, date of school reopening, in order to collect epidemiologic data about Covid-19 carriage among schoolers and to support governmental strategy for the new school year in September 2020.
Studientyp
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Nice, Frankreich
- Hôpitaux Pédiatrique de Nice CHU Lenval
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Age ranging from 3 to 10 years old
- Children attending to school in Nice
- Informed consent
- French insurance subscribed
Exclusion Criteria:
- Refusal to participate from the parents or the child
- Bleeding disorders
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Sonstiges: RT-PCR Covid-19
|
estimation of the prevalence of positive rt-PCR in school children during the pandemic period
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
evaluation of the prevalence of positive real-time-polymerase chain reaction (rt-PCR) in school children during the pandemic period in Nice
Zeitfenster: at 42 days
|
measure by two rt-PCR COVID-19 tests regardless the serological status of the child
|
at 42 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
evaluation of the serological prevalence of the Covid-19 infection
Zeitfenster: at inclusion and at 42 days
|
measure by two serological COVID-19 test (IgG and/or IgM)
|
at inclusion and at 42 days
|
|
evaluation of the COVID-19 reinfection among seropositive children at the inclusion time
Zeitfenster: at inclusion and at 42 days
|
measure by two serological COVID-19 test (IgG and/or IgM)
|
at inclusion and at 42 days
|
|
evaluation of the prevalence of positive rt-PCR of other respiratory viruses (including others coronavirus)
Zeitfenster: at 42 days
|
positivity of rt-PCR test for other viruses (adenovirus, metapneumovirus, picornavirus, respiratory syncytial virus, influenza et parainfluenza and other coronavirus strains)
|
at 42 days
|
|
comparison of inflammatory response level between different coronavirus strains
Zeitfenster: at 42 days
|
measure of level of the two inflammation biomarkers (IFIT1 interferon and CCL8)
|
at 42 days
|
|
Estimation of medico-social risk factors associated with COVID-19 infection
Zeitfenster: at 42 days
|
measure of the medico-social relative risk associated with rt-PCR COVID-19 test positivity among : school level, gender, school type, day care facilities before 11th May, number of siblings, housing type, number of bedrooms, precariousness level, by score EPICES ( (Evaluation de la Précarité et des Inégalités de santé dans les Centres d'examens de santé, means Assessment of precariousness and health inequalities in health examination centers). Questionnaire of EPICES counts 11 items, the answer to each question is assigned a coefficient, the sum of the 11 answers gives the score EPICES. The score is continuous, it varies from 0 (lack of precariousness) to 100 (maximum precariousness). |
at 42 days
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Voraussichtlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 20-HPNCL-02
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Infection; Viral, Coronavirus
-
Jianfeng XieRekrutierungCLABSI – Central Line Associated Bloodstream InfectionChina
-
Assiut UniversityNoch keine RekrutierungCLABSI – Central Line Associated Bloodstream Infection | Peripher eingeführter Zentralkatheter | Nabelschnur venöser Katheter
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Niederlande
-
National Taiwan University Hospital Hsin-Chu BranchAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
University of MalayaTeleflexAbgeschlossenCLABSI – Central Line Associated Bloodstream InfectionMalaysia
-
University of ZurichNoch keine RekrutierungCentral Line-associated Bloodstream Infection (CLABSI) | Katheterbedingte Blutstrominfektion
-
China National Center for Cardiovascular DiseasesChinese Academy of Medical Sciences, Fuwai HospitalAktiv, nicht rekrutierendLungenentzündung | Sepsis | Infektion | Driveline Heart-assisted Device Related InfectionChina
Klinische Studien zur RT-PCR Covid-19
-
University Hospital, LilleAbgeschlossenCovid19 | SARS-CoV-InfektionFrankreich
-
Centre Hospitalier Universitaire, AmiensUniversity Hospital, Rouen; University Hospital, Montpellier; Central Hospital... und andere MitarbeiterAktiv, nicht rekrutierendCOVID-19 | Hepatozelluläres KarzinomFrankreich
-
University Hospital, LilleAbgeschlossenSARS-CoV-2Frankreich
-
Assiut UniversityAbgeschlossenBewerten Sie die Ergebnisse für Kinder mit Covid-19, die im Assuit University Children Hospital aufgenommen wurdenÄgypten
-
University of RochesterEunice Kennedy Shriver National Institute of Child Health and Human Development...AbgeschlossenCovid19Vereinigte Staaten
-
BioTeke USA, LLCCSSi Life SciencesAbgeschlossen
-
EDP BiotechParagon Rx Clinical, Inc.; iCura Diagnostics, LLCAbgeschlossenCOVID-19 | SARS-CoV-2-InfektionVereinigte Staaten
-
Bangladesh Medical Research Council (BMRC)UnbekanntHohe Sensitivität und Spezifität (mit 95 % Konfidenzintervall) des RealDetect™ COVID-19 RT-PCR-KitsBangladesch
-
MP Biomedicals, LLCEDP BiotechAbgeschlossenCOVID-19 | SARS-CoV2-InfektionVereinigte Staaten
-
Kanuni Sultan Suleyman Training and Research HospitalAbgeschlossen